AC Immune SA expected to post a loss of 19 rappen a share - Earnings Preview

AC Immune SA

10/03/2025 12:33

AC Immune SA ACIU.OQ ACIU.O is expected to show a fall in quarterly revenue when it reports  results on March 12 (estimated) for the period ending December 31 2024

The Lausanne Vaud-based  company is expected to report a 95.0% decrease in revenue to CHF742.09 thousand from CHF14.8 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for AC Immune SA is for a loss of 19 rappen per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for AC Immune SA is $8.50​, above​ its last closing price of $2.41. ​​​

Previous quarterly performance (using preferred earnings measure in Swiss francs). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.19
-0.20
0.05
Beat
125.5
Jun. 30 2024
0.35
0.27
-0.23
Missed
-185.4
Mar. 31 2024
-0.13
-0.14
-0.18
Missed
-33.2​
Dec. 31 2023
-0.06
-0.11
-0.05
Beat
55.9
​​Sep. 30 2023
-0.07
0.03
-0.18
Missed
-801.2
Jun. 30 2023
-0.19
-0.20
-0.20
Met
-1.4​
Mar. 31 2023
-0.23
-0.23
-0.21
Beat
8.5
Dec. 31 2022
-0.25
-0.23
Beat
8.7

This summary was machine generated March 10 at 12:32 GMT.  All figures in Swiss francs unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)